Trivalent MDCK cell culture-derived influenza vaccine Optaflu^®(Novartis Vaccines)

This publication has 9 references indexed in Scilit:

• Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: A sequential Phase I and Phase II clinical trial
  Vaccine, 2009
• Vaccine Preparedness — Are We Ready for the Next Influenza Pandemic?
  New England Journal of Medicine, 2008
• A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture
  New England Journal of Medicine, 2008
• Lectin-affinity chromatography for downstream processing of MDCK cell culture derived human influenza A viruses
  Vaccine, 2007
• Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media
  Vaccine, 2006
• Influenza vaccines: recent advances in production technologies
  Applied Microbiology and Biotechnology, 2005
• Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children
  Vaccine, 2001
• Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture
  Vaccine, 1998
• Immunogenicity and Reactogenicity of Influenza Subunit Vaccines Produced in MDCK Cells or Fertilized Chicken Eggs
  The Journal of Infectious Diseases, 1997